BioArctic AB (BIOA_B) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to BIOATIQ's presentation for the first quarter of twenty twenty six. It has been a strong start of the year for BIOATIQ following a transformative year of 2025 with record financial results. It shows that the growth year at continuous in a great way for BIOAFIC. It's reassuring to see that more and more patients are getting access to the BIOAMEI. And we had more than €500,000,000 of sales during our partner Eisai's fiscal year. And that resulted in a commercial milestone to BIOALPIC. Our projects and our brain transporter technology are also progressing really well. And we have increased focus on business development, which is based on great interest in brain transporter and in our projects. I'll talk more about that in today's presentation. Next slide, please. BIOAARTIK is listed at Nasdaq Stockholm Northcap, and this is our disclaimer. Next slide, please. So I'm Gennila Oswald, and I'm the CEO of BIOAARTIK. And I will share today's presentation with our CFO, Anders Macklin Lehert and our Chief R and D Officer, Joanna Felting and our Chief Commercial Officer, Anna Kajagre and Blatt. Next slide, please. I will start our presentation by giving some key highlights. Next slide, please. BIOAARTIC is focusing on two different platforms in precision neurology, and we are among the world leading innovators in both areas. The first area is about creating highly selective antibodies, which is targeting aggregated misfolded forms of toxic proteins. The most advanced program here is lecanumab, lecanbi. And we also have projects targeting alpha synuclein, GDP 43 and Huntington. The second area is when we are utilizing our brain transporter platform in unique ways to deliver antibodies more efficiently into the brain. But we have now also broadened our ...